Before, patients receiving antiretroviral treatment could take up to 32 pills a day, said Lou Lange, a partner at Asset Management Ventures and founder of CV Therapeutics, a Palo Alto-based biotech company that was later sold to Gilead in 2009 for $1.4 billion. "It was just a dream really. Every discussion of ideas was anchored in application to our day-to-day work. They are carrying forward Johns legacy. May 7, 1951-March 30, 2021 "Martin, who had a background in chemical engineering and organic chemistry and had done a brief stint at Bristol-Myers Squibb, joined Gilead in 1990 with the pioneering idea that nucleotides could be used as an effective drug for HIV treatment. Truvada and Sustiva were already "the most widely prescribed antiretroviral treatment regimen in the U.S."[7] for the treatment of HIV and AIDS. His dedication to the vision of Gilead and getting quality products to the patients that needed them was an inspiration to all of us who worked for him. View Tribute Book It is with great sadness that the company has learned of the passing of Dr. Martin, whose scientific vision and leadership helped transform the lives of millions of patients and shape Gilead into the company that it is today. John Martin MBA 84, LHD 03 Former Executive Chairman at Gilead Sciences Making a Mark with Anti-Virals Under the visionary leadership of President and CEO John Martin, Gilead Sciences produced its first profit in 2002 earned both sales of $3 billion and the number three spot of distinction on the Business Week Select 50 only five years later. [20], Last edited on 17 February 2023, at 00:55, Pandemic Perspectives with John C. Martin, President's Emergency Plan for AIDS Relief, International Society for Antiviral Research, National Institute of Allergy and Infectious Diseases, Centers for Disease Control and Prevention, Presidential Advisory Council on HIV/AIDS, "Gilead's John C. Martin: One Breakthrough Drug After Another", "John Martin: Executive Profile & Biography - Businessweek", "FDA Approves Gilead, Bristol-Myers Squibb Once-a-Day Combination Antiretroviral Pill", "Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) Tablets", "HIV/AIDS Historical Time Line 2000 - 2010", "Gilead's John Martin scores 'best CEO' trophy for huge stock gains", "Gilead's $84,000 Treatment Questioned by U.S. "If you missed doses, the HIV virus could mutate and become resistant," said Lange, who continued to work on other projects with Martin after the sale of his company. His tenure in the pharmaceutical industry spanned at least four decades. "None of us who've been there need to speak on it," Samuel said. John was an E8 in the Navy. For more information on Gilead Sciences, please visit the companys website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia, Veklury (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression, Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury (Remdesivir) Due to Presence of Glass Particulates, Gilead Statement on Veklury (Remdesivir) and the SARS-CoV-2 Omicron Variant, Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir, Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy for Pre-Exposure Prophylaxis in the European Union, Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy) in Second-Line and Later Metastatic Triple-Negative Breast Cancer, Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees, Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States, Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis, Gilead Sciences Response to Open Letter Regarding Access to AmBisome (liposomal amphotericin B), Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer, Gilead Sciences Statement on Phase 3 Veklury (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19, Gilead Announces Additional Updates to The Advancing ACCESS Patient Assistance/Medication Assistance Program, Gilead Announces Updates to The Advancing ACCESS Patient Assistance/Medication Assistance Program, Gilead Announces Plans for New Location in North Carolinas Research Triangle Region Dedicated to Business Services, Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD. https://t.co/1gMZa5YtRX, Chris Garabedian (@cngarabedian) March 31, 2021, Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation Leave a sympathy message to the family on the memorial page of John Martin to pay them a last tribute. [17] He was also an Award Winner and National Finalist for the EY Entrepreneur of the Year Award. View source version on businesswire.com: Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. "It funded a number of scientists' projects in the developing world," Lange said. In addition to running Gilead, Dr. Martin was president of the International Society for Antiviral Research from 1998 to 2000. "We weren't making money or anything," Samuel said. John loved to work. He is survived by his wife, Allita M. Martin of the home; 3 children; 2 brothers; 2 sisters; a number of grandchildren. [2][6], At Gilead, Martin helped to develop Atripla, a single pill combining Gilead's drug Truvada (a combination of tenofovir and emtricitabine) with Bristol-Myers Squibb's Sustiva (efavirenz). Martin is survived by his partner, Lillian Lou, two children and three siblings, according to Johnson. Patients had a pill burden of more than 20 pills taken at multiple time points over the day. A truck circled Gileads headquarters in Foster City, Calif., in 2012 to protest the high cost of the companys anti-H.I.V. Home & Real Estate Unlock this article along with other benefits by subscribing to one of our paid plans. (That case is still pending.) Express / Weekend Express "If you missed doses, the HIV virus could mutate and become resistant," said Lange, who continued to work on other projects with Martin after the sale of his company. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. John C. Martin, who led Gilead to greatness in developing a hugely profitable HIV drug franchise, has died. "He was a visionary that really understood medical science, drug development and could take the straightest path to success," Lange said. He is survived by his wife Lisa. Marjorie Eloise Rogers. "As chief executive officer from 1996 through 2016, he steered the company through a period of remarkable growth," Gilead wrote in a statement announcing Martin's death. . Martin also started a foundation under his name with a mission to improve health care in "socially and economically-disadvantaged settings," according to the foundation's website. . Astolfo E Valenzuela. By Alex Keown. Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the company's chief executive officer from 1996 to 2016 and as its chairman from 2008 to 2019. According to a 2015 company report, Gilead had signed agreements with 11 India-based pharmaceutical manufacturers to develop generic versions of its hepatitis C medicine for 101 developing countries, from Afghanistan to Zimbabwe. According to the New York Times, the Justice Department could seek billions of dollars in royalties for Gilead's previous sales of the drug, which brings in about $3 billion each year for the company.Gilead rejected the government's complaint and has maintained that the patents were invalid. Former Sarepta CEO Gets $15M From Hedge Fund for Startup Incubator, Q&A on Drug Pricing with Gileads Gregg Alton: Outtakes From the Podcast. Johns legacy will be felt for generations to come, living on through the scientific progress made under his leadership and the programs he championed that expanded access to medications for people around the world, Daniel ODay, chairman and current CEO of Gilead Sciences said in a statement. While the companys annual revenue soared past $20 billion and its products were hailed as medical miracles, the federal Department of Health and Human Services claimed that Gilead had infringed government patents in making Truvada. FOSTER CITY, Calif.-- ( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the company's chief. John H. Clark, age 94 of Mount Gilead died on Friday, December 9, 2022, at the Woodside Village Care Center. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Womens Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP, Gilead Sciences Statement on The World Health Organizations Updated Veklury (Remdesivir) COVID-19 Treatment Guidelines, https://www.businesswire.com/news/home/20210330006163/en/. Chris Garabedian, chairman and CEO, Xontogeny. Before, patients receiving antiretroviral treatment could take up to 32 pills a day, said Lou Lange, a partner at Asset Management Ventures and founder of CV Therapeutics, a Palo Alto-based biotech company that was later sold to Gilead in 2009 for $1.4 billion. Johns legacy will be felt for generations to come, living on through the scientific progress made under his leadership and the programs he championed that expanded access to medications for people around the world, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Embarcadero Media But his most notable contributions to the company came after he was named CEO in 1996. Martin is credited as the editor.) Martin, who had a background in chemical engineering and organic chemistry and had done a brief stint at Bristol-Myers Squibb, joined Gilead in 1990 with the pioneering idea that nucleotides could be used as an effective drug for HIV treatment. That was clear. During his time with Gilead, Martin also expanded access to HIV medication in developing countries. On behalf of all of us at Gilead, I extend our deepest condolences to Johns family.. [20] He died on March 30, 2021 at a hospital in Palo Alto, California from head injuries sustained after a fall. Contact Us It was this belief that later led to Gilead's launch of tenofovir, trademarked as Viread, which was approved by the U.S. Federal Drug Administration as an anti-HIV treatment in 2001. John Martin Gilead Obituary: Gilead CEO, John Martin kicked the bucket matured 70, on March, 2021, with friends and family left in desolation. On behalf of all of us at Gilead, I extend our deepest condolences to Johns family.. To see this page as it is meant to appear, please enable your Javascript! But the little biotech from Foster City, California, over the course of a decade, reigned supreme as the worlds largest maker of HIV medicines. Can California's power grid handle a 15-fold increase in electric cars? Cynthia Muir. Martin is believed to have fallen while walking near Coleridge Avenue and Bryant Street on March 29, said Franklin Johnson, founder of Asset Management Company and a close friend of Martin, in an email. [6], In 2015 Martin was named by investment firm Morningstar as best CEO. front came in 2006, with Atripla, which combined Truvada with Bristol-Myers Squibbs Sustiva in a single pill, replacing as many as 32 separate medications that some patients were taking daily to treat the virus, which can lead to AIDS. The companys biggest advance on the H.I.V. It was this belief that later led to Gilead's launch of tenofovir, trademarked as Viread, which was approved by the U.S. Federal Drug Administration as an anti-HIV treatment in 2001. His tenure in the pharmaceutical industry spanned at least four decades. But his most notable contributions to the company came after he was named CEO in 1996.Of note is the development of Atripla, the first single-tablet regimen for treating HIV, which hit the market in 2006. John Wayne Martin, please click here to visit our Sympathy Store. Palo Alto, California. one-time use only and expires after 24 hours. "It was just a dream really.". John would later be seen at the picnic chatting with employees, watching others play volleyball and eating barbecue. But the company attracted scrutiny from health care providers and the federal government during its growth. Words cant bring Christina Aguilera down but frown lines can. Privacy | Time to read: about 4 minutes. John C. Martin, former CEO of Gilead Sciences who helped develop the first once-a-day pill to treat HIV while at the helm of the company, died unexpectedly on March 30 after suffering head injuries from a fall the previous day. Martin's death was announced by Gilead, where he served as CEO from 1996 to 2016. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data With that vision in mind, Gilead acquired Triangle Pharmaceuticals to obtain a second backbone nucleoside analogue to combine with Gileads own tenofovir. "[6], In 2003, Martin received the International Society for Antiviral Research's Gertrude B. Elion Award for Scientific Excellence in 2003. He was uninterested in the spotlight. Five years later, shortly after Martin announced he was stepping down from his role as executive chairman, the Trump administration sued the company, alleging Gilead infringed upon patents owned by the U.S. Department of Health and Human Services in order to develop Truvada as an HIV-preventative drug. He later received a doctorate in organic chemistry from the University of Chicago. Founded in 1987, Gilead Sciences was a small pharmaceutical company with a burn rate and zero revenue, according to Clifford Samuel, the company's former senior vice president of Global Patient Solutions, who started working at the company in 1996 as a sales representative. Youll be sorely missed, John! When I was tasked with leading Gilead Medical Affairs, I was supposed to move to the R&D building where my new boss, Norbert Bischofberger, was located. [2] [3] He joined Gilead Sciences in 1990 as vice president for research and development. "You really have to care about the poor and the fact that the bulk of HIV are in poor developing world countries," Samuel said. The critics were relentless and vocal. [15], In 1990,[16] Martin received the American Chemical Society's Isbell Award, "for his applications of carbohydrate chemistry to the design of medicinally active nucleosides and nucleotides. John Wayne Martin, 73, of Onvil Rd., Mt. Martin earned a bachelor's degree in chemical engineering from Purdue University,[2] an MBA in marketing from Golden Gate University and a PhD in organic chemistry from the University of Chicago. He used the opportunity to conduct his own market research to help the drive the companys clinical development pipeline strategy, anticipate objections to product adoption or exploit opportunities to position Gileads products more favorably vis--vis our competitors. Some had to be taken with food, some without. Merz has previously enlisted singer-songwriters Joe Jonas and Teyana Taylor, 33 and 31 years old respectively, who tout the anti-wrinkle injection as a solution for frown lines without any unnecessary ingredients.. The nonprofit is based in Palo Alto. That decision to stop doing antisense work was just as important as his decision shortly thereafter to bet the company on antivirals. If he wasnt, it probably meant he was traveling. Martins death was announced by Gilead, where he served as CEO from 1996 to 2016. John C. Martin, who became a billionaire by developing and marketing a daily single-dose pill that transformed H.I.V. Martin served on the council of the National Institute of Allergy and Infectious Diseases (2000-2003). His business casual attire of neutral colors and pattern-less sport coats seemed intended to not allow any distraction from his words and the ideas he wanted to convey. John Wayne Martin, 73, of Mt. Sorry, you have Javascript Disabled! Gilead, died Wednesday, September 15, 2021 at his residence. May 7, 1951-March 30, 2021 magic link that lets you log in quickly without using a password. Your contribution matters. He had served in the US Marine Corps and had worked as a Correctional Officer and in Security. [10], In 2014, Martin led the commercialization of Sovaldi (sofosbuvir) Gilead rejected the government's complaint and has maintained that the patents were invalid. Martin, a trained chemist, joined Gilead in 1990, and moved from its research director to chief executive in six years, according to the Times.He served as CEO from 1996 to 2016, and was executive chairman from 2016 until his 2018 retirement. "By 2011, Gilead accounted for almost half of the U.S. market for HIV drug production, according to the New York Times. John Charles Martin was born on May 7, 1951, in Easton, Pa., the son of Tellis Alexander Martin, a chemist for Bristol-Myers, and Janet (Sacks) Martin, who taught chemistry, physics and computer literacy at a prep school in Indiana. "You really have to care about the poor and the fact that the bulk of HIV are in poor developing world countries," Samuel said. "If you missed doses, the HIV virus could mutate and become resistant," said Lange, who continued to work on other projects with Martin after the sale of his company. As chief executive officer from 1996 through 2016, he steered the company through a period of remarkable growth. I saw his routines out of the corner of my eye. Death / Obituaries. Gilead jolted the industry with several major scientific breakthroughs, beginning with the development of the first anti-influenza pill, Tamiflu, which the company licensed to the Swiss drugmaker Hoffman-La Roche in 1996. There is a long list of Gilead alumni and current employees, like me, who would call John their most influential mentor. Martin joined Gilead in 1990. Powered by Madgex Job Board Software. John Martin, who was CEO of HIV-drug firm Gilead Sciences for two decades through 2016, died in March 2021 at age 69. Thats My Word is tackling disparities in multiple myeloma diagnosis and treatment in the Black community. FOSTER CITY, Calif.--(BUSINESS WIRE)-- (650) 358-1054 Sponsored content Palo Alto, California. Death - Obituary - Cause of Death : Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has . By 2011, Gilead accounted for almost half of the U.S. market for HIV drug production, according to the New York Times. Martin is survived by his partner, Lillian Lou, two children and three siblings, according to Johnson. "As chief executive officer from 1996 through 2016, he steered the company through a period of remarkable growth," Gilead wrote in a statement announcing Martin's death. Community Calendar Martin is survived by his partner, Lillian Lou, two children and three siblings, according to Johnson. Search Mount Gilead obituaries and condolences, hosted by Echovita.com. For more information on Gilead Sciences, please visit the companys website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. According to the New York Times, the Justice Department could seek billions of dollars in royalties for Gilead's previous sales of the drug, which brings in about $3 billion each year for the company. This was exemplified during the development and commercialization of Gileads initial HIV and HBV drugs. Roche and Exelixis are reporting a second flop out of a trio of Phase III trials designed to test a combination of their PD-L1 drug and tyrosine kinase inhibitor. By 2011, Gilead accounted for almost half of the U.S. market for HIV drug production, according to the New York Times. I didnt want to leave that office next to John, even for a promotion. Yet he left a legacy of having built one of biotechs most successful and enduring companies. Redwood City Pulse, 2023 Palo Alto Online GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL Gilead Presents Positive Proof-of-Concept Data for Investigational https://www.businesswire.com/news/home/20210330006163/en/. It was this belief that later led to Gilead's launch of tenofovir, trademarked as Viread, which was approved by the U.S. Federal Drug Administration as an anti-HIV treatment in 2001. Long after I moved on, I saw how this quiet leader continued to envision and execute on the big, long-term strategies that he set in motion in Gileads adolescent years. Some of his accolades include the American Chemical Society's Horace S. Isbell Award, which acknowledges significant research in carbohydrate chemistry and biochemistry; the International Society for Antiviral Research's Gertrude B. Elion Award for Scientific Excellence; and a Lifetime Achievement Award for Public Service from the Institute of Human Virology at the University of Maryland School. Alice Bertha Anderson. As I read about his death last week, I realized that his understated and humble style did not allow him to receive the glory that he deserved from the industry that benefited so much from his contributions. I tried to make some small talk, which was always a bit awkward. He let the companys results speak volumes. He displayed an efficiency of words that was focused on communicating with clarity about a key concept or an action to be taken. He didnt make the cover of magazines, even when he led the company that did more than any other to transform HIV into a chronic, manageable disease. While some of us left Gilead prior to Johns departure at the end of 2018 (I left in 2005), there was quite an exodus in recent years of senior leaders who spent the bulk of their careers at Gilead and have now moved on to be CEOs and board members for other companies. December 1, 2022 (89 years old) View obituary. Find an obituary, get service details, leave condolence messages or send flowers or gifts in memory of a loved one. Below is a lightly edited and condensed version of the interview. He stepped down as CEO in 2016 but maintained a role in the company as executive chairman from 2016 to 2018. [9] Purchase of Atripla was included in the President's Emergency Plan for AIDS Relief (PEPFAR) program. Unlock this story instantly and join 161,900+ biopharma pros reading Endpoints daily and it's free. Post #1138, 400 Jones Avenue, Monroe, Michigan 48161. And dont come back until the doctor agrees to join us as a medical science liaison, he added. "It funded a number of scientists' projects in the developing world," Lange said.Born on May 7, 1951, in Easton, Pennsylvania, Martin received his bachelor's degree in chemical engineering from Purdue University, a master's degree in marketing from Golden Gate University, and a doctorate in organic chemistry from the University of Chicago.His tenure in the pharmaceutical industry spanned at least four decades.In 1978, he joined Syntex Laboratories, which was headquartered in Palo Alto. From 1984 to 1990, he was the director of antiviral chemistry at Bristol-Myers Squibb. Martin first joined Gilead, a biopharmaceutical company based in Foster City, in 1990 as the vice president of its research and development department. Welcome back to Endpoints Weekly, your review of the weeks top biopharma headlines. Martin is credited with taking Sovaldi from "zero-to-blockbuster in a couple of months" with profits topping $10 billion for 2014. Rowland Heights, CA 91748. Briggs Funeral Home. Become a Member Billed annually at $107.40. 2161 Fullerton Road. The effort centers on pledges, or people giving their word, to spread information and increase awareness. He argued, among other things, that high prices for successful products were needed to subsidize future research. The nonprofit is based in Palo Alto. "It was just a dream really.". This close working relationship extended beyond researchers and clinicians to the patient community. He was 70 years old. We'll e-mail you a link to set a new password. Gilead rejected the government's complaint and has maintained that the patents were invalid. John R. Martin John R. Martin, age 84, of Winterhaven, CA, passed away Dec. 22, 2022 in Yuma, AZ. | Funeral Home Website by Batesville Home | Sign up here. He stepped down as CEO in 2016 but maintained a role in the company as executive chairman from 2016 to 2018.Some of his accolades include the American Chemical Society's Horace S. Isbell Award, which acknowledges significant research in carbohydrate chemistry and biochemistry; the International Society for Antiviral Research's Gertrude B. Elion Award for Scientific Excellence; and a Lifetime Achievement Award for Public Service from the Institute of Human Virology at the University of Maryland School.Martin is survived by his partner, Lillian Lou, two children and three siblings, according to Johnson. - Click to learn more.. Courtesy Lou Lange. John C. Martin, who led Gilead to greatness in developing a hugely profitable HIV drug franchise, has died. According to the New York Times, the Justice Department could seek billions of dollars in royalties for Gilead's previous sales of the drug, which brings in about $3 billion each year for the company. A chemist by training, he turned Gilead Sciences into a leading, and lucrative, innovator with single-pill treatments for H.I.V. My first few months at Gilead were spent traveling the world visiting every top expert HBV clinician to learn about the disease, the current state of treatment and what outcomes would be most meaningful. November 5, 2022 (87 years old) View obituary. 1996-2023 Gilead Sciences, Inc. All rights reserved. Please note the magic link is When he died last week at age 70, Martin was essentially unknown to the public and not very well understood within his own industry. October 28, 2022 (81 years old) View obituary. At the end of a meeting with John, there was little room for interpretation or doubt about what to do next. In 1978, he joined Syntex Laboratories, which was headquartered in Palo Alto. Admin. He was 70 years old. Born on May 7, 1951, in Easton, Pennsylvania, Martin received his bachelor's degree in chemical engineering from Purdue University, a master's degree in marketing from Golden Gate University, and a doctorate in organic chemistry from the University of Chicago. On one hand, this agent offers up to a 95% response rate as part of an interferon-free treatment regimen for hepatitis C.6 Generally speaking, it is more effective and better tolerated than alternative treatments.6 Unfortunately, the current per pill cost$1,000results in an $84,000 treatment course, creating barriers to therapy for many.6 Patients, providers, and payors alike have expressed outrage, and the debate has even drawn the attention of the US Congress.7 Despite these concerns, sofosbuvir rapidly has become a top seller in the United States. John C. Martin, former CEO of Gilead Sciences who helped develop the first once-a-day pill to treat HIV while at the helm of the company, died unexpectedly on March 30 after suffering head injuries from a fall the previous day. Pricing and access to medicines were perennial thorny issues at Gilead. John began his career at Gilead in 1990, as vice president of Research & Development. "We weren't making money or anything," Samuel said. John Martin Obituary With heavy hearts, we announce the death of John Martin (Fountain Inn, South Carolina), born in Columbia, South Carolina, who passed away on February 4, 2023. While almost every rare disease company knows the power of engaging with patient advocates, John was doing it with many HIV advocates in a thoughtful, sensitive and collaborative manner long before it was vogue. "We developed the drug; we invented it.". He read philosophy with practical aims in mind.